Skip to main content
. 2015 Sep 5;6(31):31313–31322. doi: 10.18632/oncotarget.5182

Figure 2. Ibrutinib anti-tumor efficacy in PC-9 and H1975 xenograft mouse models.

Figure 2

A. Ibrutinib slows down tumor progression in a PC-9 xenograft model at 25 mg/Kg, 50 mg/Kg, 100 mg/Kg BID; B. Ibrutinb slightly slowed down tumor progression in an H1975 xenograft model at 50 mg/Kg, 100 mg/Kg BID; C. Combination study with Ibrutinib and GSK1120212 showed combinatorial anti-proliferation effect against H1975 cells; D. Combination of ibrutinib (50 mg/Kg) and GSK1120212(10 mg/Kg) in H1975 xenograft model.